Core #2 Preclinical testing Milton V. Marshall, Ph.D. DABTThe preclinical core will provide services to the NTR program to develop safety and toxicity profiles ofcandidate imaging agents. Facilities are available in our satellite facility at BCM to house rodents for safetyand toxicity testing of molecular imaging agents. Should larger animals be needed, additional space isavailable through the BCM Center for Comparative Medicine (CCM). CCM personnel who work on GLPstudies have received training in Good Laboratory Practices, and some personnel have previous workexperience in a GLP facility. Thus, facilities and personnel are available to conduct GLP-compliant preclinicalsafety and toxicity studies as needed under this program. Dr. Marshall has experience in drug developmentusing different animal models, including rodents, dogs, and primates; his work in preclinical medical devicedevelopment includes use of farm animals (sheep, pigs, and calves). Brian Gibson, DVM, will work with Dr.Marshall in study design and in monitoring the health of animals on safety studies. Because BCM does notmaintain a GLP-compliant clinical chemistry and hematology laboratory, samples will be sent to a local GLPcompliantfacility, Equine Laboratories. Likewise, histopathology will be conducted at a GLP-compliant facility,and slides will be reviewed by a board-certified Veterinary Pathologist with experience in preclinical drug anddevice development.
Showing the most recent 10 out of 39 publications
